JP2007524105A - 結合物質 - Google Patents

結合物質 Download PDF

Info

Publication number
JP2007524105A
JP2007524105A JP2007500291A JP2007500291A JP2007524105A JP 2007524105 A JP2007524105 A JP 2007524105A JP 2007500291 A JP2007500291 A JP 2007500291A JP 2007500291 A JP2007500291 A JP 2007500291A JP 2007524105 A JP2007524105 A JP 2007524105A
Authority
JP
Japan
Prior art keywords
binding
population
partner
substance
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007500291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524105A5 (https=
Inventor
セルフ，コリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2007524105A publication Critical patent/JP2007524105A/ja
Publication of JP2007524105A5 publication Critical patent/JP2007524105A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
JP2007500291A 2004-02-25 2005-02-25 結合物質 Pending JP2007524105A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0404187.7A GB0404187D0 (en) 2004-02-25 2004-02-25 Binding agents
PCT/GB2005/000704 WO2005083431A2 (en) 2004-02-25 2005-02-25 Binding agents

Publications (2)

Publication Number Publication Date
JP2007524105A true JP2007524105A (ja) 2007-08-23
JP2007524105A5 JP2007524105A5 (https=) 2008-04-10

Family

ID=32050854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500291A Pending JP2007524105A (ja) 2004-02-25 2005-02-25 結合物質

Country Status (5)

Country Link
US (1) US20080107660A1 (https=)
EP (1) EP1723418A2 (https=)
JP (1) JP2007524105A (https=)
GB (1) GB0404187D0 (https=)
WO (1) WO2005083431A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511033A (ja) * 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
JP2019523635A (ja) * 2016-05-02 2019-08-29 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
JP2023529982A (ja) * 2020-06-19 2023-07-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化型ｔ細胞二重特異性抗体
US11782062B2 (en) 2017-10-31 2023-10-10 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547324B2 (ja) * 2005-11-24 2010-09-22 シャープ株式会社 タンパク質認識構造体、タンパク質認識基板、及びこれらの製造方法
GB0707870D0 (en) 2007-04-23 2007-05-30 Selected Antibodies Ltd Assay Devices and Methods and Components for use Therein
GB0716160D0 (en) * 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
WO2011101435A1 (en) * 2010-02-19 2011-08-25 Novo Nordisk A/S Activatable constructs
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014040129A1 (en) * 2012-09-12 2014-03-20 The University Of Queensland Protease-based biosensor
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
EP3044322A4 (en) 2013-09-12 2017-09-06 The University Of Queensland Bimolecular protease-based biosensor
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
US20160362469A1 (en) * 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
BR112019011564A2 (pt) 2016-12-09 2019-10-22 Seattle Genetics Inc anticorpos bivalentes mascarados por hélices superenroladas
AU2018225164A1 (en) * 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
CN114072499B (zh) 2019-04-30 2024-08-06 Encodia公司 用于制备分析物的方法和相关试剂盒
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505108A (ja) * 1995-05-03 1999-05-18 バイオエンハンスメンツ リミテッド 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体
WO2002060488A1 (en) * 2001-01-30 2002-08-08 Universite Catholique De Louvain Anti-tumor compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849478A (en) * 1986-08-14 1998-12-15 Cashman; Daniel P. Blocked-polymerase polynucleotide immunoassay method and kit
GB9322156D0 (en) * 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
US5468785A (en) * 1994-04-15 1995-11-21 University Of Akron Cobaloxime photoinitiated free radical polymerizations
WO1999053102A1 (en) * 1998-04-16 1999-10-21 Packard Bioscience Company Analysis of polynucleotide sequence
EP1112378A1 (en) * 1998-07-17 2001-07-04 GeneTag Technology, Inc. Methods for detecting and mapping genes, mutations and variant polynucleotide sequences
US6203989B1 (en) * 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
EP1349943A2 (en) * 2001-01-04 2003-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Detection of protein conformation using a split ubiquitin reporter system
US20030082191A1 (en) * 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505108A (ja) * 1995-05-03 1999-05-18 バイオエンハンスメンツ リミテッド 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体
WO2002060488A1 (en) * 2001-01-30 2002-08-08 Universite Catholique De Louvain Anti-tumor compounds

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511033A (ja) * 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
US12235276B2 (en) 2016-05-02 2025-02-25 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12123878B2 (en) 2016-05-02 2024-10-22 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
JP7120630B2 (ja) 2016-05-02 2022-08-17 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US12517133B2 (en) 2016-05-02 2026-01-06 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
JP7333975B2 (ja) 2016-05-02 2023-08-28 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US12320813B2 (en) 2016-05-02 2025-06-03 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
JP2022065157A (ja) * 2016-05-02 2022-04-26 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US11959922B2 (en) 2016-05-02 2024-04-16 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12019077B2 (en) 2016-05-02 2024-06-25 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12019078B2 (en) 2016-05-02 2024-06-25 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
JP2019523635A (ja) * 2016-05-02 2019-08-29 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US12130291B2 (en) 2017-10-31 2024-10-29 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
US12292446B2 (en) 2017-10-31 2025-05-06 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
US11782062B2 (en) 2017-10-31 2023-10-10 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
JP2023529982A (ja) * 2020-06-19 2023-07-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化型ｔ細胞二重特異性抗体
JP7815150B2 (ja) 2020-06-19 2026-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化型ｔ細胞二重特異性抗体

Also Published As

Publication number Publication date
WO2005083431A2 (en) 2005-09-09
EP1723418A2 (en) 2006-11-22
GB0404187D0 (en) 2004-03-31
US20080107660A1 (en) 2008-05-08
WO2005083431A3 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
JP2007524105A (ja) 結合物質
JP7000489B2 (ja) ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
Niki et al. Comparison of glial fibrillary acidic protein and desmin staining in normal and CCl4‐induced fibrotic rat livers
AU2003234327B2 (en) Binary or polynary targeting and uses thereof
JP2503319B2 (ja) 抗体結合体を用いる抗原の検出および／または分離方法
US5855886A (en) Antibodies, and methods for their use
EP0871673B1 (en) Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
US20050095627A1 (en) Multiple antigen detection assays and reagents
TW202014436A (zh) 抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法
JPH0576960B2 (https=)
KR101290034B1 (ko) 표적 물질의 검출 방법
JP4334065B2 (ja) 抗体のフレームワーク領域から誘導される物質によるイムノアッセイの干渉の減少
JPH09507754A (ja) 哺乳類悪性細胞の選択的メチオニン飢餓方法
AU660445B2 (en) Fusion proteins for prodrug activation, the preparation and use thereof
Wring et al. Shorter development of immunoassay for drugs: application of the novel RIMMS technique enables rapid production of monoclonal antibodies to ranitidine
JP2005518431A (ja) 高分子コンジュゲート及びその製造方法
WO1995011703A9 (en) Nitrophenyl derivatives that can be activated by light
WO1995011703A1 (en) Nitrophenyl derivatives that can be activated by light
KR20220088437A (ko) 폴리뉴클레오티드-연결된 바이오컨쥬게이트 및 제조 및 이용 방법
JP3568198B2 (ja) 異常プリオンタンパク質の検出方法
JP3036545B2 (ja) モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法
JPS61213671A (ja) ヒトプラスミン−α↓２−プラスミンインヒビタ−複合体の測定法
CA2332121A1 (en) Methods for inhibiting tef-3 activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110705